Forma Therapeutics Holdings (FMTX) Reports In-Line Q1 EPS

May 14, 2021 7:09 AM EDT
Get Alerts FMTX Hot Sheet
Price: $25.35 +4.62%

Today's EPS Names:
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Forma Therapeutics Holdings (NASDAQ: FMTX) reported Q1 EPS of ($0.76), in-line with the analyst estimate of ($0.76).

“During the first quarter, we successfully completed the multiple ascending dose portion of our Phase 1 trial in sickle cell disease, and despite challenges from the COVID-19 pandemic also began enrolling patients in the Phase 2/3 trial of FT-4202, called The Hibiscus Study, as well as in the Phase 1 trial of FT-7051 for metastatic castration resistant prostate cancer,” said Frank Lee, President and Chief Executive Officer of Forma. “We look forward to sharing additional pipeline results over the course of 2021 in our mission to transform the lives of people living with rare hematologic diseases and cancers.“

For earnings history and earnings-related data on Forma Therapeutics Holdings (FMTX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities